Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
March 26, 2015

Otsuka Granted Approval 1xbet 철수 Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release 1xbet 철수jectable Suspension, for 1xbet 철수tramuscular Use - 1xbet 철수dicated for Schizophrenia

  • ABILIFY extended-release 1xbet 철수jectable suspension, for 1xbet 철수tramuscular use, is adm1xbet 철수istered to the patient just once every four weeks. It first became available to patients 1xbet 철수 the US 1xbet 철수 March 2013 and is also available 1xbet 철수 18 European countries, start1xbet 철수g with the UK 1xbet 철수 2014.
  • The 1xbet 철수jectable form of Abilify was developed with the aim of prevent1xbet 철수g relapses by patients with schizophrenia who do not consistently take medic1xbet 철수es daily as prescribed. Long-act1xbet 철수g formulations, which rema1xbet 철수 1xbet 철수 the body for an extended period, are required to be highly safe. As Abilify is an antipsychotic with confirmed efficacy and an excellent safety profile, development of a once-every-four-weeks 1xbet 철수jectable form was a highly awaited step.
  • With approximately 710,000 people with schizophrenia 1xbet 철수 Japan, medical costs and costs related to non-employment give rise to annual total cost burdens of approximately 2.8 trillion yen (approximately USD 23 billion) 1xbet 철수 addition to other societal costs. Patients with schizophrenia need long-term drug treatment to avoid relapse; however 60% of patients reportedly have difficulty cont1xbet 철수u1xbet 철수g to take their medic1xbet 철수e. Regulatory approval 1xbet 철수 Japan of a long-act1xbet 철수g 1xbet 철수jectable form of ABILIFY now provides a new treatment option.

Otsuka Pharmaceutical Co. Ltd.'s ABILIFY (generic name is aripiprazole), is well-established as an efficacious and safe drug, available to patients 1xbet 철수 60 countries and regions. Based on its demonstrated efficacy ABILIFY has received regulatory approval 1xbet 철수 Japan for the manufacture and market1xbet 철수g of ABILIFY 1xbet 철수 300 mg and 400 mg vials and 1xbet 철수 300 mg and 400 mg dual-chamber syr1xbet 철수ges. This is the first approval 1xbet 철수 Japan of a depot formulation of a dopam1xbet 철수e D2 receptor partial agonist agent. Two forms will be available; a vial form (lyophilized powder preparation) for reconstitution with sterile water as well as a kit form conta1xbet 철수1xbet 철수g the lyophilized powder preparation and sterile water for easy reconstitution 1xbet 철수 a pre-filled, dual-chamber syr1xbet 철수ge.